HomeCompareVBIV vs BTI

VBIV vs BTI: Dividend Comparison 2026

VBIV yields 3062.79% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBIV wins by $553925093173.78M in total portfolio value
10 years
VBIV
VBIV
● Live price
3062.79%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$553925093173.82M
Annual income
$520,495,004,530,333,300.00
Full VBIV calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — VBIV vs BTI

📍 VBIV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBIVBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBIV + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VBIV pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBIV
Annual income on $10K today (after 15% tax)
$260,336.91/yr
After 10yr DRIP, annual income (after tax)
$442,420,753,850,783,300.00/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, VBIV beats the other by $442,420,753,850,780,900.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBIV + BTI for your $10,000?

VBIV: 50%BTI: 50%
100% BTI50/50100% VBIV
Portfolio after 10yr
$276962546586.93M
Annual income
$260,247,502,265,168,060.00/yr
Blended yield
93.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

VBIV
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBIV buys
0
BTI buys
0
No recent congressional trades found for VBIV or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBIVBTI
Forward yield3062.79%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$553925093173.82M$37.8K
Annual income after 10y$520,495,004,530,333,300.00$2,802.29
Total dividends collected$551616311074.85M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: VBIV vs BTI ($10,000, DRIP)

YearVBIV PortfolioVBIV Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$316,979$306,278.71$11,301$601.08+$305.7KVBIV
2$9,412,423$9,073,255.39$12,799$706.58+$9.40MVBIV
3$261,868,365$251,797,073.09$14,527$832.38+$261.85MVBIV
4$6,827,292,278$6,547,093,127.32$16,527$982.75+$6827.28MVBIV
5$166,830,733,833$159,525,531,095.41$18,846$1,162.95+$166830.71MVBIV
6$3,821,633,158,895$3,643,124,273,693.35$21,545$1,379.49+$3821633.14MVBIV
7$82,083,497,792,692$77,994,350,312,674.64$24,694$1,640.41+$82083497.77MVBIV
8$1,653,448,854,533,535$1,565,619,511,895,354.20$28,378$1,955.69+$1653448854.51MVBIV
9$31,243,073,498,582,136$29,473,883,224,231,256.00$32,702$2,337.79+$31243073498.55MVBIV
10$553,925,093,173,816,260$520,495,004,530,333,300.00$37,794$2,802.29+$553925093173.78MVBIV

VBIV vs BTI: Complete Analysis 2026

VBIVStock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Full VBIV Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this VBIV vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBIV vs SCHDVBIV vs JEPIVBIV vs OVBIV vs KOVBIV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.